Substitution of pioglitazone for troglitazone in patients with type 2 diabetes

Endocrine Practice

Volumn 10, Issue 1, 2004, Pages 18-23

  Kane, Michael P ^a   Busch, Robert S ^b   Bakst, Gary ^b   Hamilton, Robert A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Endocrine Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CHROMAN DERIVATIVE; PIOGLITAZONE; TROGLITAZONE;

AGED; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT OUTCOME;

AGED; CHROMANS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 3242891451     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.10.1.18     Document Type: Article

References (33)

1. Hogan P, Dall T, Nikolov P (American Diabetes Association). Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26:917-932.
2. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet. 1993;341:1306-1309.
3. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329:304-309.
4. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
5. Klein R, Klein BE, Moss SE, Cruickshanks KJ. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med. 1994;154:2169-2178.
6. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [erratum in Lancet. 1999;354:602]. Lancet. 1998;352:837-853.
8. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [erratum in Lancet. 1998;352:1557]. Lancet. 1998;352:854-865.
9. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003;26(Suppl 1):S33-S50.
10. Reaven GM. Banting lecture: role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
11. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-957.
12. Schwartz S, Raskin P, Fonseca V, Graveline JF (Troglitazone and Exogenous Insulin Study Group). Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med. 1998;338:861-866.
13. Buse JB, Gumbiner B, Mathias NP, Nelson DM, Faja BW, Whitcomb RW (Troglitazone Insulin Study Group). Troglitazone use in insulin-treated type 2 diabetic patients. Diabetes Care. 1998;21:1455-1461.
14. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones [erratum in Ann Intern Med. 2001;135:307]. Ann Intern Med. 2001;134:61-71.
15. King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones [letter]. Diabetes Care. 2000;23:557.
16. Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice [erratum in Endocr Pract. 2001;7:330]. Endocr Pract. 2001;7:162-169.
17. Davidson PC, Sabbah HT, Steed RD, Richardson P, Robertson DG, Bode BW. Pioglitazone versus rosiglitazone therapy in randomized follow-up in patients previously treated with troglitazone [abstract from the ADA 61st Scientific Sessions]. Diabetes. 2001;50(Suppl 1):A109, 437-P.
18. King AB, Armstrong D. Comparison of the glucose and lipid effects of rosiglitazone (ROS) and pioglitazone (PIO) following conversion from troglitazone (TRO) treatment [abstract from the ADA 61st Scientific Sessions]. Diabetes. 2001;50(Suppl 1):A120, 482-P.
19. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care. 2002;25: 708-711.
20. Bell DSH, Ovalle F, Shadmany S. Conversion from troglitazone to rosiglitazone [abstract from the ADA 60th Scientific Sessions]. Diabetes. 2000;49(Suppl 1):A353, 1481-PO.
21. Boyle PJ, King AB, Olansky L, et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther. 2002;24:378-396.
22. Kane MP, Busch RS, Bakst G, Hamilton RA. The safety and efficacy of troglitazone in a private-practice endocrinology group [abstract from the ADA 59th Scientific Sessions]. Diabetes. 1999;48(Suppl 1):A360, 577-PO.
23. Actos [package insert]. Lincolnshire, IL: Takeda Pharmaceuticals America, Inc, 2000.
24. Turner RC, Cull CA, Frighi V, Holman RR (UK Prospective Diabetes Study [UKPDS] Group). Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999; 281:2005-2012.
25. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281-303.
26. Viberti G, Kahn SE, Greene DA, et al. A Diabetes Outcome Progression Trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care. 2002;25:1737-1743.
27. Kelly IE, Han TS, Walsh K, Lean ME. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes [erratum in Diabetes Care. 1999;22:536]. Diabetes Care. 1999;22:288-293.
28. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87:2784-2791.
29. National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity, and health risk. Arch Intern Med. 2000;160:898-904.
30. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723-1727.
31. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens. 1995;8:316-320.
32. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994;331:1188-1193.
33. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498-511.